Roche shifts funding priorities
Pharmaceutical company Roche seems to be changing up its research focus. The company is pulling the plug on its HIV research program, and today offered more than $40 billion to buy up the 44% of biotech Genentech that it does not already own. A Roche spokesperson told linkurl:Chemical & Engineering News;https://pubs.acs.org/cen/news/86/i29/8629notw7.html that there are no drugs in the company's HIV drug pipeline that warrant further development. They had been developing antiretrovirals, all of w
Written byAndrea Gawrylewski
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred Google source to see more of our trusted coverage.
Meet the Author
Andrea Gawrylewski worked at The Scientist from 2007 to 2009.
View Full Profile
